Abstract
Cardiovascular disease is the most common cause of sickness and death for long-term kidney transplant recipients, and dyslipidemia is an important risk factor for developing cardiovascular disease. Lipid-lowering strategies, with the use of statins, have been shown to reduce the cardiovascular risks related to dyslipidemia, but concomitant use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and immunosuppressive agents may increase the risk of rhabdomyolysis owing to a drug-drug interaction. We report a case of simvastatin-induced rhabdomyolysis and acute kidney injury triggered by addition of sirolimus and cisplatin-based chemotherapy to a kidney transplant recipient who had previously tolerated chronic statin therapy.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acute Kidney Injury / chemically induced
-
Acute Kidney Injury / diagnosis
-
Acute Kidney Injury / therapy
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
-
Cisplatin / adverse effects
-
Drug Interactions
-
Dyslipidemias / complications
-
Dyslipidemias / diagnosis
-
Dyslipidemias / drug therapy*
-
Fatal Outcome
-
Female
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects*
-
Immunosuppressive Agents / adverse effects*
-
Kidney Transplantation / adverse effects*
-
Lung Neoplasms / drug therapy*
-
Middle Aged
-
Renal Dialysis
-
Rhabdomyolysis / chemically induced*
-
Rhabdomyolysis / diagnosis
-
Rhabdomyolysis / therapy
-
Risk Factors
-
Severity of Illness Index
-
Simvastatin / adverse effects*
-
Sirolimus / adverse effects*
-
Time Factors
-
Treatment Outcome
Substances
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Immunosuppressive Agents
-
Simvastatin
-
Cisplatin
-
Sirolimus